Companies striving to become compliant with the FMD must consider a wide range of factors. From selecting the right hardware and software, to training staff and ensuring that their packing lines will not be disrupted, there is a lot to put in place.

It is now unlikely that all companies will achieve compliance on time without halting production.

Although many companies have devoted time and resources to making sure that they can continue as normal, some are less prepared for serialisation requirements. The reality of the situation is that these companies may not be able to continue producing and distributing products post-February 2019.

Find out more about how pharma companies are preparing for the upcoming changes and the current state of the industry by reading our latest article here: https://issuu.com/pfmagazine/docs/pf_magazine_january_2019/20